Bayer chooses Metra bone resorbtion assay:
This article was originally published in Clinica
Bayer will market Metra Biosystems' Pyrilinks-D deoxypyridinoline (Dpd) bone resorbtion test worldwide, with the exception of Japan, as an automated assay on its Immuno 1 system. The test is already offered by Chiron Diagnostics and Diagnostic Products on their automated platforms. The test measures Dpd, the accepted bone resorbtion marker, which is excreted in the urine in an unmetabolised form and is the only recognised test on the market, according to the company.
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.